Peptide dual agonists of gipr and glp2r
AssigneeUniversity of Copenhagen
InventorsBolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
Life of this patent
Estimating the term…
Abstract
Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
Claims20
A peptide dual agonist of the GIPR (glucose-dependent insulinotropic polypeptide receptor) and of the GLP2R (glucagon-like peptide-2 receptor), said peptide comprising
- (SEQ ID NO:
- 21)
- HX20X21GTFISDYSTILDNLAARDFX22NWLX23X24X25KX26X27X28,
- where X20 is selected from A, V and G,
- X21 is selected from D and E,
- X22 is selected from I and V,
- X23 is selected from I and L,
- X24 is selected from Q and A,
- X25 is selected from T and Q,
- X26 is selected from I and G,
- X27 is selected from T and K, and
- X28 is selected from D and K,
- or a functional variant thereof having 1, 2, 3 or 4 individual amino acid substitutions, wherein said functional variant comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GIPR and the GLP-2R.
A method of inhibiting bone resorption and stimulating bone formation comprising administering a therapeutically effective amount of a peptide dual agonist of the GIPR and of the GLP2R, said peptide comprising
- (SEQ ID NO:
- 21)
- HX20X21GTFISDYSTILDNLAARD
- FX22NWLX23X24X25KX26X27X28,
- wherein X20 is selected from A, V and G,
- X21 is selected from D and E,
- X22 is selected from I and V,
- X23 is selected from I and L,
- X24 is selected from Q and A,
- X25 is selected from T and Q,
- X26 is selected from I and G,
- X27 is selected from T and K, and
- X28 is selected from D and K,
- or a functional variant thereof having 1, 2, 3 or 4 individual amino acid substitutions, wherein said functional variant comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GI PR and the GLP-2R.
A method treating a bone disorder comprising administering a therapeutically effective amount of a peptide dual agonist of the GIPR and of the GLP2R, said peptide comprising the sequence
- (SEQ ID NO:
- 21)
- HX20X21GTFISDYSTILDNLAARDF
- X22NWLX23X24X25KX26X27X28,
- wherein X20 is selected from A, V and G,
- X21 is selected from D and E,
- X22 is selected from I and V,
- X23 is selected from I and L,
- X24 is selected from Q and A,
- X25 is selected from T and Q,
- X26 is selected from I and G,
- X27 is selected from T and K, and
- X28 is selected from D and K,
- or a functional variant thereof having 1, 2, 3 or 4 individual amino acid substitutions, wherein said functional variant comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GIPR and the GLP-2R.
Dependencies are inferred from the claim text.